An insight into the invasion of breast ductal carcinoma
Breast cancer
Invasion
Ductal Carcinoma in situ
Hematological indicator
Pathological marker
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
06
2022
accepted:
08
08
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
7
9
2022
Statut:
epublish
Résumé
Ductal carcinoma Medical records of 389 patients diagnosed with DCIS or DCIS with invasive ductal carcinoma (IDC) were reviewed. All of them received appropriate medical care in our center. All 324 patients in training cohort were divided into invasion and non-invasion groups based on pathology. Differences in DCIS immunohistochemical markers and hematological indicators between them were analyzed. In the invasion group, differences between DCIS and matched IDC were compared to explore changes in the tumor heterogeneity during invasion. Conclusions are validated in the validation cohort of 65 patients. Patients in invasion and non-invasion groups were balanced in baseline characteristics and no statistically significant differences were noticed for DCIS immunohistochemical markers. For hematological indicators, high expression of platelet >291.50) (odds ratio, 2.46; CI [1.35-4.46]; The change in hematological indicators is an independent predictor for invasion and can be incorporated into the treatment decision-making process for DCIS. Invasion tumor cells exhibit a stronger proliferative capacity compared with the
Sections du résumé
Background
Ductal carcinoma
Methods
Medical records of 389 patients diagnosed with DCIS or DCIS with invasive ductal carcinoma (IDC) were reviewed. All of them received appropriate medical care in our center. All 324 patients in training cohort were divided into invasion and non-invasion groups based on pathology. Differences in DCIS immunohistochemical markers and hematological indicators between them were analyzed. In the invasion group, differences between DCIS and matched IDC were compared to explore changes in the tumor heterogeneity during invasion. Conclusions are validated in the validation cohort of 65 patients.
Results
Patients in invasion and non-invasion groups were balanced in baseline characteristics and no statistically significant differences were noticed for DCIS immunohistochemical markers. For hematological indicators, high expression of platelet >291.50) (odds ratio, 2.46; CI [1.35-4.46];
Conclusion
The change in hematological indicators is an independent predictor for invasion and can be incorporated into the treatment decision-making process for DCIS. Invasion tumor cells exhibit a stronger proliferative capacity compared with the
Identifiants
pubmed: 36065403
doi: 10.7717/peerj.13966
pii: 13966
pmc: PMC9440660
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e13966Informations de copyright
©2022 Liu et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Ann Oncol. 2001;12 Suppl 1:S97-100
pubmed: 11521731
Front Oncol. 2021 Sep 10;11:717198
pubmed: 34568047
Am J Surg. 2018 Nov;216(5):998-1003
pubmed: 30244816
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Front Pharmacol. 2022 Jun 16;13:880445
pubmed: 35784753
Cancer. 2008 May 15;112(10):2130-42
pubmed: 18383519
Surgery. 1993 Feb;113(2):134-7
pubmed: 8381562
J Natl Compr Canc Netw. 2020 Apr;18(4):452-478
pubmed: 32259783
Cancer. 2005 May 1;103(9):1778-84
pubmed: 15770688
J Clin Oncol. 2021 Jul 20;39(21):2367-2374
pubmed: 33739848
Breast Cancer Res Treat. 2013 Nov;142(2):415-21
pubmed: 24202240
J Am Coll Surg. 2019 Jun;228(6):932-939
pubmed: 30772444
Lancet. 2003 Jul 12;362(9378):95-102
pubmed: 12867108
Chin J Cancer. 2017 Sep 12;36(1):75
pubmed: 28899420
Cancer Cell. 2013 Jul 8;24(1):9-11
pubmed: 23845439
Biochimie. 2020 Aug;175:69-76
pubmed: 32422159
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Br J Cancer. 2001 Sep 14;85(6):869-74
pubmed: 11556839
Ann Surg Oncol. 2011 May;18(5):1342-8
pubmed: 21042943
N Engl J Med. 1993 Jun 3;328(22):1581-6
pubmed: 8292119
Cancer Res. 2005 Aug 15;65(16):7241-8
pubmed: 16103075
Lancet. 1999 Jun 12;353(9169):1993-2000
pubmed: 10376613
Arch Pathol Lab Med. 2010 Jun;134(6):907-22
pubmed: 20524868
Acta Histochem. 2016 Jun;118(5):544-52
pubmed: 27246286
Curr Probl Surg. 1996 Jul;33(7):553-600
pubmed: 8765465
Adv Anat Pathol. 2014 Mar;21(2):100-7
pubmed: 24508693
Front Oncol. 2020 Apr 21;10:580
pubmed: 32373539
Cancer. 1997 Nov 1;80(9):1740-5
pubmed: 9351542
Adv Clin Exp Med. 2015 Sep-Oct;24(5):899-903
pubmed: 26768643
Zhonghua Wai Ke Za Zhi. 2015 Aug 1;53(8):634-7
pubmed: 26653966
Annu Rev Med. 2017 Jan 14;68:197-211
pubmed: 28099081
Clin Chim Acta. 2018 Sep;484:272-277
pubmed: 29860033
Cytojournal. 2012;9:4
pubmed: 22363393
J Clin Oncol. 2021 Oct 20;39(30):3409-3410
pubmed: 34473527
Nat Rev Immunol. 2011 Jul 25;11(8):519-31
pubmed: 21785456
Cell Metab. 2021 Jul 6;33(7):1307-1321
pubmed: 33915111
J Clin Oncol. 2010 Sep 10;28(26):4045-51
pubmed: 20644090
Mod Pathol. 2002 Dec;15(12):1318-25
pubmed: 12481013
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Arch Pathol Lab Med. 2007;131(1):18-43
pubmed: 19548375
Cancer. 2005 Jun 15;103(12):2481-4
pubmed: 15884091
Am J Surg Pathol. 2019 Nov;43(11):1574-1582
pubmed: 31206365
Aging (Albany NY). 2022 Apr 12;14(7):3276-3292
pubmed: 35413690